Harvard Bioscience To Showcase Latest Solutions For Preclinical And Organoid Applications At Society Of Toxicology Meeting
Harvard Bioscience To Showcase Latest Solutions For Preclinical And Organoid Applications At Society Of Toxicology Meeting
哈佛生物科學將在毒理學會會議上展示臨床前和類器官應用的最新解決方案
Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
哈佛生物科學公司（納斯達克股票代碼：HBIO）今天宣佈，它將在2024年3月11日至13日在鹽湖城舉行的毒理學會（SOT）會議上展示其最新的產品創新。這些新創新補充了本已廣泛的產品線，爲推進臨床前和以類器官爲中心的療法開發提供了令人興奮的新機會。
DSI Ponemah Data Management Platform Provides Integrated Preclinical Solution
DSI Ponemah 數據管理平台提供集成的臨床前解決方案
The Company's industry-leading GLP-compliant Ponemah preclinical data management platform now includes integrations with the new SoHo implantable telemetry solution and the VivaMARS high-capacity behavior monitoring system.
該公司業界領先的符合GLP標準的Ponemah臨床前數據管理平台現在包括與新的SoHo植入式遙測解決方案和VivaMars高容量行爲監測系統的集成。
By integrating these new applications in a single data management platform...
通過將這些新應用程序集...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。